Zanidatamab with chemo for HER2-positive bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with HER2-positive bile duct or gallbladder cancer that has grown after first treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with bile duct or gallbladder cancer that cannot be removed by surgery or has spread.
- Your tumor tests positive for HER2 (a protein that helps cancer grow).
- Your cancer got worse after or you could not tolerate a standard first treatment that included an immunotherapy drug (PD-1/PD-L1 inhibitor).
- You have at least one tumor that can be measured on scans.
- You are generally able to take care of yourself (ECOG performance status 0 or 1).
- Your organ function (blood, liver, kidneys, heart) is adequate.
- You have not been treated before with irinotecan, capecitabine, or any HER2-targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
This trial tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) for people with advanced bile duct cancer that has a protein called HER2. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a drug called zanidatamab for people with advanced solid tumors that have a specific marker called HER2. It may help if you've already tried one or more standard treatments.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.